Does the mouse tail vein injection method provide a good model of lung cancer? [version 1; peer review: 2 approved]

Lung cancer drug development requires screening in animal models. We aimed to develop orthotopic models of human non-small lung cancer using A549 and H3122 cells delivered by tail vein injection. This procedure has been used previously for a mouse lung cancer (Lewis lung carcinoma) and as a model of...

Full description

Saved in:
Bibliographic Details
Published inF1000 research Vol. 8; p. 190
Main Authors Shrestha, Nensi, Lateef, Zabeen, Martey, Orleans, Bland, Abigail R, Nimick, Mhairi, Rosengren, Rhonda, Ashton, John C
Format Journal Article
LanguageEnglish
Published England Faculty of 1000 Ltd 2019
F1000 Research Limited
F1000 Research Ltd
Subjects
Animal models
Breast cancer
Drug development
Experiments
Immunohistochemistry
Injection
Kinases
Lung cancer
Lung carcinoma
Metastases
Methods
Microscopy
Necropsy
Ostomy
Thromboembolism
Veins & arteries
lung cancer
mouse model
tail vein
human cells
Online AccessGet full text

Cover

More Information
Summary:Lung cancer drug development requires screening in animal models. We aimed to develop orthotopic models of human non-small lung cancer using A549 and H3122 cells delivered by tail vein injection. This procedure has been used previously for a mouse lung cancer (Lewis lung carcinoma) and as a model of human breast cancer metastasis to lung. We report that the procedure led to poor animal condition 7-8 weeks after injection, and produced lesions in the lungs visible at necropsy but we were unable identify individual cancer cells using immunohistochemistry. We conclude that if this method is to produce a model that can be used in drug experiments, improvements are required for cancer cell detection post mortem, such as by using of a fluorescently tagged human lung cancer cell line.
Bibliography:No competing interests were disclosed.
ISSN:2046-1402
2046-1402
DOI:10.12688/f1000research.17964.1